Aytu Biopharma, Inc. last reported quarterly results on Apr 2, 2026, for Q3 FY2026 (the quarter ended Mar 31, 2026): revenue of $12.4 million (-32.7% year over year) and diluted EPS of -$0.53. It usually reports 2–44 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 2–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Apr 2, 2026
2 days after quarter end
|
Q3 FY2026
ended Mar 31, 2026
|
12
-32.7%
|
-6
-240.7%
|
-0.53
-352.4%
|
|
Feb 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Dec 31, 2025
|
15
-6.5%
|
-11
-1443.1%
|
-1.05
-303.8%
|
|
Nov 13, 2025
44 days after quarter end
|
Q1 FY2026
ended Sep 30, 2025
|
14
-16.2%
|
2
+33.3%
|
-0.08
+46.7%
|
|
May 14, 2025
44 days after quarter end
|
Q3 FY2025
ended Mar 31, 2025
|
18
+31.6%
|
4
+238.3%
|
0.21
|
|
Feb 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Dec 31, 2024
|
16
-13.5%
|
1
+458.2%
|
-0.26
|
|
Nov 13, 2024
44 days after quarter end
|
Q1 FY2025
ended Sep 30, 2024
|
17
-7.0%
|
1
+118.2%
|
-0.15
+89.9%
|
|
May 15, 2024
45 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Feb 14, 2024
45 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AYTU (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Denver, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1385818
- Former names
- AYTU BIOSCIENCE, INC (until Mar 22, 2021); Rosewind CORP (until Jun 8, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.